ZURICH, Oct 3 (Reuters) - Swiss drugmaker Novartis will send a letter to U.S. doctors in the next few days to warn that there is a risk that its cancer drug Gleevec could cause heart damage, a spokesman said.
ZURICH, Oct 3 (Reuters) - Swiss drugmaker Novartis will send a letter to U.S. doctors in the next few days to warn that there is a risk that its cancer drug Gleevec could cause heart damage, a spokesman said.
